JAMA reports fluvoxamine as potential early treatment for COVID-19

(Allison PR Limited) The COVID-19 Early Treatment Fund (CETF) announced thatJAMA,The Journal of the American Medical Association, published the results of a Washington University School of Medicine in St. Louis double-blind, randomized controlled clinical trial that investigated whether the antidepressant medication fluvoxamine can reduce the risk for respiratory deterioration.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news